Quick Facts

• Therapeutic Domains: Pain management, inflammation, and fever.
• Approved Use: Short-term management of mild to moderate pain, including certain muscle or joint discomfort and menstrual pain.

---

Arveles (dexketoprofen) is authorized for use in the short-term management of mild to moderate painful conditions. Its therapeutic profile is concentrated on relieving discomfort and addressing swelling associated with various sources of pain.

Healthcare professionals may consider this compound for patients experiencing musculoskeletal pain, such as that resulting from sprains or strains. It is also utilized for the management of dental pain and to mitigate the symptoms of menstrual pain (dysmenorrhea). Additionally, the compound is employed to reduce fever when it is a contributing symptom to the patient's condition. The established applications focus on temporary, acute instances of discomfort.

Arveles, which contains the active substance dexketoprofen (a non-steroidal anti-inflammatory drug or NSAID), is indicated for the short-term symptomatic treatment of mild to moderate acute pain in adults. This includes pain associated with musculoskeletal issues, painful menstruation (dysmenorrhea), and dental pain.

---

Contraindications (Who Should Not Use Arveles)

Arveles is not suitable for everyone. It is contraindicated and should not be used in the following patient groups:

Condition/Group	Reason for Contraindication
Allergy	Hypersensitivity to dexketoprofen, other NSAIDs, or any component of the medication.
Gastrointestinal Issues	Active peptic ulcer, gastrointestinal bleeding, perforation, or chronic indigestion (dyspepsia).
Bleeding Disorders	Any active bleeding or a pre-existing bleeding disorder.
Severe Organ Impairment	Severe heart failure, moderate-to-severe kidney (renal) dysfunction, or severe liver (hepatic) impairment.
Pregnancy/Lactation	Women in the third trimester of pregnancy and those who are breastfeeding.
Pediatric Use	Patients under 18 years of age, as safety and efficacy have not been established.

---

Precautions (Use with Caution)

Use of Arveles requires careful medical consultation and supervision for patients with a history of heart disease (such as mild heart failure or controlled hypertension), mild-to-moderate kidney or liver problems, Crohn's disease, or ulcerative colitis. Elderly patients are also at a higher risk of adverse effects, particularly gastrointestinal bleeding, and should be started on the lowest effective dose.

Interactions with other medicines and products

Arveles (dexketoprofen) is an NSAID and its regulatory profile details clinically significant interactions primarily based on pharmacodynamic additive effects and pharmacokinetic exposure modifications.

Inadvisable Combinations and Precautions

Officially documented information strongly advises against co-administration with several medicinal product categories:

• Other NSAIDs, including COX-2 Inhibitors and high-dose Salicylates (e.g., Aspirin): These combinations are inadvisable due to a synergistic effect that significantly increases the risk of serious gastrointestinal ulceration and bleeding.
• Anticoagulants and Heparins (e.g., Warfarin): The drug may enhance the effect of these agents by inhibiting platelet function and displacing them from plasma proteins. If co-administration is necessary, close clinical and laboratory monitoring is required.

Clinically Relevant Interactions

Interacting Product Category	Regulatory Statement	Practical Implication
Diuretics, ACE Inhibitors, AIIAs	May diminish the anti-hypertensive effect and increase the risk of nephrotoxicity.	Requires caution, especially in elderly or volume-depleted patients.
Lithium or Methotrexate	Decreased renal excretion of these drugs leads to increased plasma concentrations and potential toxicity.	Monitoring of plasma levels is necessary.

Population-Specific Constraint: Patients with compromised renal function or who are elderly have a heightened risk for adverse outcomes from these interactions. Administration with food delays the drug's absorption, a pharmacokinetic consideration relevant to acute pain management.

How Arveles Works

Arveles (dexketoprofen) is a non-steroidal anti-inflammatory drug (NSAID) that exerts its pharmacodynamic effects primarily through the modulation of the arachidonic acid cascade.

---

Inhibition of Cyclooxygenase (COX) Enzymes

Arveles acts within the enzymatic domain by inhibiting the activity of cyclooxygenase (COX) enzymes. This binding interaction, a foundational molecular step, prevents the enzymatic conversion of arachidonic acid into key signaling intermediates.

---

Modulation of Prostanoid Synthesis

This inhibition results in a substantial alteration in the downstream synthesis and concentration of various prostanoids, including prostaglandins and thromboxanes, which are lipid-based signaling mediators. This cascade modifies the signaling dynamics within targeted pathways by reducing the availability of these specific mediators.

---

Systemic Physiological Consequence

The mechanistic action subsequently influences early molecular steps that shape systemic physiological responses. By engaging with pathways that regulate typically dysregulated cellular processes, Arveles alters signaling patterns associated with specific physiological states.

How Arveles is Used: Official Administration Guidelines

Arveles (dexketoprofen) is administered through distinct routes with specific dosing and scheduling protocols for short-term use. The medicine is available as oral forms (tablets and granules for solution) and parenteral forms (solution for injection/infusion).

---

Administration Scope

Instruction Entity	Standard Administration Protocol
Route of Administration	Approved routes include Oral, Intramuscular (IM) injection, Intravenous (IV) bolus, and Intravenous (IV) infusion.
Dosing Schedule (Adults)	Oral: 12.5 mg every 4 to 6 hours or 25 mg every 8 hours. Parenteral: 50 mg every 8 to 12 hours.
Maximum Daily Dose	Oral: 75 mg. Parenteral: 150 mg.
Timing in Relation to Meals	Oral doses for acute discomfort are recommended at least 15 to 30 minutes before meals to maximize absorption.
Duration Constraint	Oral: Limited to short-term symptomatic treatment. Parenteral: Limited to the acute symptomatic period, generally no more than two days.

---

Procedural and Population Rules

For older adults and those with mild renal or hepatic impairment, therapy must be initiated at a reduced total daily dose of 50 mg. Regarding parenteral use, the solution must be administered protected from natural daylight. The IV bolus is given over no less than 15 seconds. If a dose is missed, standard procedure involves skipping the missed dose and continuing with the next scheduled dose at the correct time, without doubling up. The overall use protocol is structured to provide multiple daily doses over a limited duration, demanding strict adherence to the defined dose intervals and total daily maximums.

Research Evidence / Overview of Studies for Arveles

Evidence for Use in Acute Postoperative Pain

The majority of the research for Arveles was evaluated in studies exploring how symptoms change over time following surgical procedures. This includes adults undergoing procedures such as dental extractions or minor non-dental surgeries. Studies explored how symptoms evolved in the observed populations by utilizing randomized controlled trials (RCTs) and systematic reviews. In these trials, researchers examined patient-reported outcomes describing perceived discomfort using pain scales and evaluated the need for supplemental pain medication over defined time intervals.

The findings describe patterns observed in the studies where participants experienced measured changes in pain intensity shortly after administration. Research describes changes measured during the study period concerning the time required for participants to perceive initial changes in pain levels. The results apply only to the populations studied, which were generally healthy adults undergoing specific surgical models.

---

Evidence for Use in Acute Musculoskeletal Pain

Arveles was observed in studies focusing on conditions associated with acute or disruptive episodes, such as sprains and strains. This research examined patients experiencing short-lived, outcomes capturing phases of heightened symptom activity in areas like the lower back or neck. The study designs typically included RCTs, and the key outcomes was studied for included reported changes in pain intensity and measurements of outcomes reflecting daily functioning or activity level during the recovery period.

A key limitation here is that there is limited information for long-term outcomes regarding the use of Arveles for chronic or recurring conditions marked by functional limitations. The existing research focuses predominantly on the initial, acute episode and does not extend to long-term management strategies.

---

What is Still Uncertain About Arveles' Research Evidence

The overall evidence landscape for Arveles shows that while many randomized controlled trials research examined acute pain, the follow-up durations were limited. The trials also included monitoring for safety patterns during these limited-duration studies, which provides context for the short-term focus of the research. This means the research provides context for acute episodes but not for chronic, continuous conditions.

Furthermore, comparative evidence is lacking in certain scenarios, and evidence quality varies across studies depending on the specific pain condition being explored. Finally, the research provides context but not individual predictions; the findings describe group patterns and reflect the specific conditions under which they were conducted, meaning certainty remains low for long-term use or for populations not extensively studied.

Key Studies & References

1. Systematic review of dexketoprofen in acute and chronic pain
2. Effectiveness and Safety of Oral Dexketoprofen for Mild to Moderate Pain among Filipino Adults: A Post-marketing Surveillance Study
3. Summary EU-Risk Management Plan ES/H/0101/006/MR (Dexketoprofen safety and population data)

Common questions about Arveles (FAQ)

---

Q: What is the active ingredient in Arveles?

A: The active substance in Arveles is dexketoprofen. Specifically, it is formulated as the trometamol salt, which is a chemical attribute noted in its development. This information is detailed in the official composition sections of regulatory documents.

---

Q: Can Arveles be used to treat a fever?

A: Official product information notes that Arveles belongs to the class of non-steroidal anti-inflammatory drugs (NSAIDs) which have antipyretic properties. This means the medication can help reduce fever in addition to relieving pain and inflammation.

---

Q: Who should NOT take Arveles?

A: Official regulatory documents list specific conditions where Arveles is contraindicated (should not be used). These conditions include active peptic ulcers, gastrointestinal bleeding, severe heart or liver failure, or a history of allergic reactions to aspirin or other NSAIDs. These conditions mean the medication is contraindicated.

---

Q: Is Arveles safe to take during the first trimester of pregnancy?

A: Regulatory information indicates that use of Arveles during the first and second trimesters of pregnancy is not recommended. Official information also notes that the drug is strictly contraindicated (must not be used) starting from the third trimester of pregnancy.

---

Q: What is the recommended dose of Arveles for someone with severe kidney impairment?

A: The official product information states that Arveles is contraindicated—meaning it should not be used—in patients with severely impaired kidney function. As a result, regulatory documents do not provide a recommended dose for this population.

---

Q: Can I drink alcohol while I am taking Arveles?

A: Regulatory documents for NSAIDs generally advise caution regarding the consumption of alcohol while taking these medications. Official product information cautions that combining alcohol with NSAIDs may increase the potential risk of serious side effects, particularly gastrointestinal bleeding.

How to Store and Dispose of Arveles

Official regulatory documents define strict conditions for the storage and disposal of Arveles (dexketoprofen) to maintain its quality and ensure safety.

Storage Requirements

The medicine must be stored at a temperature below 30°C. It is mandatory to keep the product in the original package, as this protects the medicine from light. Like all medications, Arveles must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired Arveles must not be disposed of in household wastewater (flushing down the toilet or sink) or with regular household trash. Disposal must comply with local regulations for pharmaceutical waste. Patients are advised to return the product to a pharmacist for proper, environmentally safe discarding.